Tania Moujaber

92-94 Parramatta Rd
Camperdown, NSW 2050, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Seasonal variation in immune-related adverse events in advanced cancer patients.

Seasonal variation in immune-related adverse events in advanced cancer patients.

Journal: Cancer immunology, immunotherapy : CII

Published: March 20, 2026

Characterising the effect of circulating sphingolipids on metastatic prostate cancer cells.

Characterising the effect of circulating sphingolipids on metastatic prostate cancer cells.

Journal: EBioMedicine

Published: January 22, 2025

Bone Health Management in Men Commencing Androgen Deprivation Therapy for Prostate Cancer and Women Commencing Anti-Oestrogen Therapy for Breast Cancer.

Bone Health Management in Men Commencing Androgen Deprivation Therapy for Prostate Cancer and Women Commencing Anti-Oestrogen Therapy for Breast Cancer.

Journal: Cancer medicine

Published: September 12, 2024

Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapy.

Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapy.

Journal: Therapeutic advances in medical oncology

Published: September 09, 2024

A Single Center Review of Patients Undergoing High-Dose Chemotherapy for Relapsed Germ-Cell Tumors.

A Single Center Review of Patients Undergoing High-Dose Chemotherapy for Relapsed Germ-Cell Tumors.

Journal: Asia-Pacific journal of clinical oncology

Published: September 25, 2023

Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centres.

Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centres.

Journal: Cancer medicine

Published: September 15, 2022

Dual-energy x-ray absorptiometry assessment of bone health in Australian men with prostate cancer commencing androgen deprivation therapy.

Dual-energy x-ray absorptiometry assessment of bone health in Australian men with prostate cancer commencing androgen deprivation therapy.

Journal: The Medical journal of Australia

Published: April 25, 2022

New therapeutic opportunities for women with low-grade serous ovarian cancer.

New therapeutic opportunities for women with low-grade serous ovarian cancer.

Journal: Endocrine-related cancer

Published: September 28, 2021

Immune-Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review of Clinical Outcomes.

Immune-Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review of Clinical Outcomes.

Journal: Cancers

Published: July 30, 2021

PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.

PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.

Journal: Gynecologic oncology

Published: April 01, 2019

BRAF Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition.

BRAF Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition.

Journal: JCO precision oncology

Published: November 01, 2018

EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas.

EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas.

Journal: Cancer research

Published: August 16, 2016

Showing 1-12 of 13

Last Updated: 09/26/2026